Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: Results from JMTO LC 0004

Journal of Thoracic Oncology

Volumn 4, Issue 9, 2009, Pages 1104-1110

  Isa, Shun Ichi ^a   Kawaguchi, Tomoya ^a   Teramukai, Satoshi ^b   Minato, Koichi ^c   Ohsaki, Yoshinobu ^d   Shibata, Kazuhiko ^e   Yonei, Toshirou ^f   Hayashibara, Kenji ^g   Fukushima, Masanori ^b   Kawahara, Masaaki ^a   Furuse, Kiyoyuki ^h   Mack, Philip C ⁱ  

^a NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c Gunma Cancer Center   (Japan)

^d ASAHIKAWA MEDICAL COLLEGE   (Japan)

^e Kouseiren Takaoka Hospital   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION   (Japan)

^g National Hospital Organization Ibaraki Higashi National Hospital The Center of Chest Diseases and Severe Motor Intellectual Disabilities   (Japan)

^h Translational Research Informatics Center   (Japan)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BFGF; Correlative study; Non small cell lung cancer; Osteopontin

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CARBOPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; OSTEOPONTIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; JAPANESE; LABORATORY TEST; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TUMOR LOCALIZATION;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; OSTEOPONTIN; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 69549097610     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181ae2844     Document Type: Article

References (26)

1. 'Cancer Statistics in Japan' Editorial Board. Number of Deaths and Proportional Mortality Rates from Malignant Neoplasms by Site in Japan (2005). Tokyo: Foundation for Promotion Cancer Research; 2005.
2. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
3. Toyoda Y, Nakayama T, Ioka A, Tsukuma H. Trends in lung cancer incidence by histological type in Osaka, Japan. Jpn J Clin Oncol 2008;38:534-539.
4. Kubota K, Kawahara M, Ogawara M, et al. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. Lancet Oncol 2008;9:1135-1142.
5. Gandara TK, Crowley JJ, Moon J, et al. Pharmacogenomic (PG) analysis of Japan-SWOG common arm study in advanced stage non-small cell lung cancer (NSCLC): a model for testing population-related pharmacogenomics. Presented at American Society of Clinical Oncology Annual Meeting, Chicago, June 1-5, 2007.
6. Mack PC, Redman MW, Chansky K, et al. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol 2008;26:4771-4776.
7. Rodrigues LR, Teixeira JA, Schmitt FL, Paulsson M, Lindmark-Mänsson H. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev 2007;16:1087-1097. (Pubitemid 46984943)
8. Hu DD, Lin EC, Kovach NL, Hoyer JR, Smith JW. A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta 5. J Biol Chem 1995;270:26232-26238.
9. Katagiri YU, Sleeman J, Fujii H, et al. CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res 1999;59:219-226. (Pubitemid 29062981)
10. Liaw L, Skinner MP, Raines EW, et al. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest 1995;95:713-724.
11. Senger DR, Perruzzi CA, Papadopoulos A. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res 1989;9:1291-1299. (Pubitemid 19277158)
12. Chambers AF, Behrend EI, Wilson SM, Denhardt DT. Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells. Anticancer Res 1992;12:43-47.
13. Oates AJ, Barraclough R, Rudland PS. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene 1996;13:97-104. (Pubitemid 26248549)
14. Tuck AB, Arsenault DM, O'Malley FP, et al. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 1999;18:4237-4246.
15. Hu Z, Lin D, Yuan J, et al. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 2005;11:4646-4652. (Pubitemid 41557181)
16. Donati V, Boldrini L, Dell'Omodarme M, et al. Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res 2005;11:6459-6465. (Pubitemid 41338982)
17. Basilico C MD. The FGF family of growth factors and oncogenes. Adv Cancer Res 1992;59:115-165.
18. Yamanaka Y, Friess H, Buchler M, et al. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res 1993;53:5289-5296. (Pubitemid 23333401)
19. Ueno K, Inoue Y, Kawaguchi T, Hosoe S, Kawahara M. Increased serum levels of basic fibroblast growth factor in lung cancer patients: relevance to response of therapy and prognosis. Lung Cancer 2001;31:213-219. (Pubitemid 32107018)
20. Kaye FJ. Publishing negative data: beta-tubulin mutations in lung cancer. J Natl Cancer Inst 2001;93:1832-1833.
21. Tsurutani J, Komiya T, Uejima H, et al. Mutational analysis of the beta-tubulin gene in lung cancer. Lung Cancer 2002;35:11-16. (Pubitemid 34028085)
22. Chambers AF, Wilson SM, Kerkvliet N, O'Malley FP, Harris JF, Casson AG. Osteopontin expression in lung cancer. Lung Cancer 1996;15:311-323. (Pubitemid 26399511)
23. Kurata T, Matsuo K, Takada M, et al. Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer? J Thorac Oncol 2006;1:684-691. (Pubitemid 47163957)
24. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006;51:143-158. (Pubitemid 43144358)
25. Yiangou C, Gomm JJ, Coope RC, et al. Fibroblast growth factor 2 in breast cancer: occurrence and prognostic significance. Br J Cancer 1997;75:28-33. (Pubitemid 27007269)
26. Grant SC, Gralla RJ, Kris MG, et al. Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients. J Clin Oncol 1992;10:484-498.